June 21, 2000--Agilent Technologies Inc. (NYSE:A - news) today announced the first release of the Rosetta Resolver(TM) Expression Data Analysis System for life science research, marking the beginning of a series of exclusive gene expression technologies resulting from the strategic alliance between Agilent and Rosetta Inpharmatics Inc. The alliance, announced last December, is expected to result in new tools that will greatly accelerate the work of researchers as they begin analyzing the vast quantities of data generated by the genomics revolution.
The Rosetta Resolver is a turnkey, enterprise-wide, gene-expression, bioinformatics solution for the pharmaceutical, biotechnology, and agriculture industries that enables researchers to simultaneously monitor multiple pathways and targets within a cell -- a capability referred to as ``comprehensive target profiling.'' When combined with Agilent's innovative DNA microarray technologies, Rosetta Resolver gives scientists a powerful tool to quickly identify new target genes of interest in the quest for new drugs and foods.
The Rosetta Resolver system combines software, hardware and database architecture to enable storage, retrieval and high-level analysis of massive volumes of expression data. This solution is ideal for pharmaceutical, biotechnology and agricultural companies needing to assess compound specificity, identify new genes or targets, or compare compound profiles to gold standards for existing drugs or agrochemicals. This enterprise-wide system combines flexibility and ease of use with high-performance algorithms to produce rapid, accurate results from complex gene expression data. The system can accept and analyze data from most commonly used expression profiling technologies, and from single or multiple experiments.
``We are pleased to offer the exclusive Rosetta Resolver bioinformatics system to our customers in Europe, Japan and the U.S. who are using gene expression analysis to identify new drug candidates. Agilent is committed to providing the highest caliber tools to enable drug discovery and the Rosetta Resolver system will strongly complement our current DNA microarray offering,'' said Richard D. (Rick) Kniss, senior vice president and general manager of Agilent's Chemical Analysis Group. ``Our customers will now be able to glean a lot more information from their arrays through access to this software that offers powerful advanced visualization and analysis capabilities for mining gene expression array data in an enterprise-wide solution.'' |
